Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

Autor: Kuruvilla, John *, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A, Fogliatto, Laura Maria, Goncalves, Iara, de Oliveira, Jose S R, Buccheri, Valeria, Perini, Guilherme F, Goldschmidt, Neta, Kriachok, Iryna, Dickinson, Michael, Komarnicki, Mieczyslaw, McDonald, Andrew, Ozcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Nahar, Akash, Marinello, Patricia, Zinzani, Pier Luigi
Zdroj: In The Lancet Oncology April 2021 22(4):512-524
Databáze: ScienceDirect